Bayer Avelox Cardiac Safety Studies Recommended By FDA Committee

Cardiac QT prolongation associated with Bayer's fluoroquinolone Avelox (moxifloxacin) should be evaluated in high risk patients, FDA's Anti-Infective Drugs Advisory Committee concluded Oct. 21.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet